Tirzepatide: Primary and completion of P3 SURMOUNT-ADOLESCENTS trial (NCT06075667) in adolescent participants who have obesity or overweight with weight-related comorbidities in Oct 2026 (Eli Lilly) - Feb 6, 2024 - Q4 2023 Results: Primary completion and completion of P3 SURMOUNT-MMO trial (NCT05556512) on the reduction on morbidity and mortality in adults with obesity in Oct 2027
Trial completion date • Trial primary completion date • Metabolic Disorders • Obesity
|